The U.S. drug regulator on Friday added a warning with the Pfizer Inc /BioNTech and Moderna COVID vaccine shots literature that denotes the possibility of a rare risk of heart inflammation after it is administered.
For each vaccine, the fact sheets for healthcare providers have been revised to include a warning that reports of adverse events suggest increased risks of myocarditis and pericarditis, particularly after the second dose and with the onset of symptoms within a few days after vaccination, the FDA said.
The cases appear to be notably higher in males and in the week after the second vaccine dose. Health regulators in several countries have been investigating cases of myocarditis and pericarditis, more frequently found in young men, after a shot of Pfizer or Moderna, vaccines that are based on the mRNA technology.
The latest update from FDA follows an extensive review of information and the discussion by CDC’s Advisory Committee on Immunization Practices meeting on Wednesday. As of June 11, more than 1,200 cases of myocarditis or pericarditis have been reported to the U.S. Vaccine Adverse Event Reporting System (VAERS), out of about 300 million mRNA vaccine doses administered.
Pfizer and Moderna have been tight-lipped about the development
Meanwhile, Infectious disease experts are weighing the need for booster shots of the Pfizer/BioNTech or Moderna mRNA-based vaccines for Americans who received Johnson & Johnson’s one-dose vaccine due to the increasing prevalence of the more contagious Delta variant.
The debate centers on concerns over how protective the J&J shot is against the Delta variant first detected in India and now circulating widely in many countries.
Delta, which has also been associated with more severe disease, could quickly become the dominant version of the virus in the United States, Centres for Disease Control and Prevention (CDC) Director Rochelle Walensky has warned.
There is no substantial data showing how protective the J&J vaccine is against the new variant. However, UK studies show that two doses of either the Pfizer/BioNTech or AstraZeneca vaccines are significantly more protective against the variant than one.
J&J said it is testing whether the immune response from its vaccine is capable of neutralizing the Delta variant in a laboratory setting, but no data is available yet.
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is running a trial to determine the need for boosting all currently authorized shots with another dose of Moderna’s vaccine.
Cases, hospitalizations, and deaths have substantially reduced in the United States as 56% of the adult population is now fully vaccinated.
VC LAB comes out with free funding documents for start ups
Aaron Segal Aims To Make Investing In Crypto More Accessible For The Everyday Investor
US news : Average mortgage rates jump ;FDA advises booster shot for COVID
Karat pioneers the Interviewing Cloud to transform technical hiring with $110M funding
A Sneak Peek Into Real Estate Agent Taylor Travaglione’s Upcoming Educational Platform
Idahome Solar Makes Transition to Solar Seamless
Donny Gillies, Metallica’s “Court Painter” Partners with Trust Me Vodka to Adorn the Next 20,000-bottle Collection
Andrew Parry’s BTC Mine Australia Sets The Global Efficiency Standard For Bitcoin Mining
Twitter to allow you to remove followers without blocking them
Netflix ties with Walmart to open hub with unique merchandise
News1 month ago
Indian billionaire Prakash Hinduja is on trial for human trafficking – his son Ajay is also suspected of tax evasion and forgery
Business2 months ago
U.S. approves first arms sale to Taiwan as its citizens ready to party
Business1 year ago
Airlines from US are expecting to get another aid package for $25 billion to keep business from falling
Markets6 months ago
Stocks close higher after two days of fall as UiPath’s stock rises 23% in Market Debut
Business10 months ago
5 ‘value investing’ Sin Stocks of 2021- An Investor Telegraph Exclusive .
Business5 months ago
Top 5 Clean Energy Companies for 2021
Business11 months ago
Delta hints at possible purchase of Boeing’s 737 MAX : Financial Times
Business11 months ago
Chinese jet ready to challenge Airbus and Boeing, C 919 in final testing stage